KemPharm, Inc. Receives Positive Feedback From FDA on KP201 Clinical Plan

Published: Nov 20, 2012

NORTH LIBERTY, Iowa--(BUSINESS WIRE)--KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today a successful Type B meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201. The meeting was held to obtain input from the Agency in regard to the remaining clinical and non-clinical program required for submission of a new drug application (NDA) for KP201.

Back to news